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Abstract: Recent investigations suggest an involvement of sphingosine-1-phosphate (S1P) in the pathogenesis of allergic 
bronchial asthma. However, the role of S1P in the development of asthma is still controversial. Our aim was to investigate 
the effects of intranasal application of S1P on antigen-induced airway inflammation in a mouse model of allergic 
bronchial asthma. 
Methodology: Male BALB/c mice were actively sensitized with ovalbumin antigen, and were repeatedly challenged with 
aerosolized antigen. Animals also received an intranasal administration of S1P (10
-5 M, 20 L) or its vehicle (1% 
methanol in sterile PBS, 20 L) 30 min prior to each antigen challenge. Histological examinations of the lungs and 
determination of cell number in the bronchoalveolar lavage fluids (BALFs) were studied. 
Results: The airway inflammation induced by antigen exposure was significantly augmented by the intranasal 
administration of S1P: the cell number in BALFs of the S1P-treated, antigen-challenged mice (S1P-Challenged, 48.9±4.8 
x 10
4/mL BALF) was significantly increased as compared with those of the vehicle-treated, antigen-challenged ones 
(Vehicle-Challenged, 26.3±5.7 x 10
4/mL BALF, P<0.01). 
Conclusion: In mice, the intranasal administration of S1P might aggravate the antigen-induced airway inflammation. 
Keywords: Sphingosine-1-phosphate (S1P), intranasal administration, allergic bronchial asthma, airway inflammation, mouse. 
INTRODUCTION 
  The dramatic increase in the number of asthma cases 
over the last decades is of great concern for public health in 
the world [1]. Allergic bronchial asthma is characterized by 
structural and functional abnormalities of the bronchial 
epithelium, accumulation of inflammatory cells in the 
bronchial mucosa, remodeling of the airway tissue structure, 
and airway hyperresponsiveness. Many mediators have been 
identified that play significant roles in the initiation and 
progression of the disease, but the exact mechanism of the 
pathogenesis of asthma is still unclear. 
 Sphingosine-1-phosphate (S1P) is a bioactive 
sphingolipid metabolite that mediates diverse biological 
responses [2-6]. Recently, an involvement of S1P in allergic 
bronchial asthma has been suggested [7-13]. Ammit and 
colleagues [7] firstly demonstrated that S1P levels are 
elevated in the airways of individuals with asthma after 
segmental allergen challenge. The finding that S1P can act as 
a chemotactic agent for eosinophils further suggests an 
involvement of S1P in pathophysiology of asthma [8]. 
Indeed, inhalation of inhibitors for sphingosine kinase 
(SphK), which produces S1P directly from sphingosine, 
attenuated antigen-induced airway inflammation in mice [9]. 
In addition, S1P might have an ability to cause airway 
hyperresponsiveness [10-13], one of the characteristic   
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features of allergic bronchial asthma. Contrary to these 
observations, an intratracheal instillation of FTY720, an S1P 
receptor agonist, prevented antigen-induced airway 
inflammation and hyperresponsiveness in mice [14]. Thus, 
the role of S1P in the development of asthma is still 
controversial. 
  In the present study, the effects of pretreatment with S1P 
by intranasal administration on antigen-induced inflammatory 
signs of the airways were determined in a murine model of 
allergic bronchial asthma. 
METHODS 
Animals and Treatments 
  Male BALB/c mice were purchased from the Charles 
River Japan, Inc. (Kanagawa, Japan) and housed in a 
pathogen-free facility. All animal experiments were 
approved by the Animal Care Committee of the Hoshi 
University (Tokyo, Japan). 
  Preparation of a murine model of allergic bronchial 
asthma, which has an in vivo AHR [15], was performed as 
described previously [16-20]. In brief, BALB/c mice (8 
weeks of age) were actively sensitized by intraperitoneal 
injections of 8 g ovalbumin (OA; Seikagaku Co., Tokyo, 
Japan) with 2 mg Imject Alum (Pierce Biotechnology, Inc., 
Rockfold, IL, USA) on Day 0 and Day 5. The sensitized 
mice were challenged with aerosolized OA-saline solution (5 
mg/mL) for 30 min on Days 12, 16 and 20. The OA aerosol 
was generated with an ultrasonic nebulizer (Nihon Kohden, 
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(130 x 200 mm, 100 mm height) in which the mice were 
placed. The animals also received intranasal administration 
of S1P (10
-5 M, 20 L) or its vehicle (1% methanol in sterile 
PBS, 20 L) 30 min prior to each antigen challenge by the 
method previously described [18]. The dose of S1P was 
decided based on the previous report [7]. Twenty-four hours 
after the last OA challenge, mice were sacrificed by 
exsanguination from abdominal aorta under urethane (1.6 
g/kg, i.p.; Sigma and Aldrich, St. Louis, MO) anesthesia. 
Then histologic examination and cell count in 
bronchoalveolar lavage (BAL) fluid were carried out by the 
methods previously described [18]. 
Statistical Analyses 
  The cell counts data were expressed as the mean with 
S.E. Statistical significance of difference was determined by 
unpaired Student's t-test or two-way analysis of variance 
(ANOVA) with post hoc Bonferroni/Dunn (StatView for 
Macintosh ver. 5.0, SAS Institute, Inc., NC). A value of 
p<0.05 was considered significant. 
RESULTS AND DISCUSSION 
  In the present study, we used our well-established murine 
model of allergic bronchial asthma [16-20]. Histochemical 
examination using hematoxylin and eosin staining revealed a 
marked lung inflammation in the repeatedly antigen-
challenged mice (Fig. 1C) as compared with the control 
animals (Fig. 1A): a marked infiltration of inflammatory 
cells, mainly eosinophils, was observed in the lungs of the 
antigen-challenged mice. The inflammation score determined as 
previously described [19] was significantly increased in 
lungs of the antigen-challenged mice (2.4±0.4) than that of 
the control animals (0.9±0.3, P<0.05). To further quantify 
the airway inflammation, cell counts in bronchoalveolar 
lavage (BAL) fluids were carried out. As shown in Fig. (2), 
the cell counts in BAL fluids of the repeatedly antigen-
 
Fig. (1). Histological examinations of lungs from the repeatedly antigen-challenged (Challenged; C and D) and control mice (Control; A and 
B). Animals were also received intranasal administration of sphingosine-1-phosphate (S1P; 10
-5 M, 20 L) or its vehicle (1% methanol in 
sterile PBS, 20 L) 30 min prior to each antigen exposure. Four-m sections of formalin-fixed lung tissues were stained with hematoxylin 
and eosin before examination by light microscopy. The photos shown are Vehicle-Control (A), S1P-Control (B), Vehicle-Challenged (C), 
and S1P-Challenged groups (D), and are representative of 3 different animals, respectively. Original magnification: x80. 84    The Open Respiratory Medicine Journal, 2010, Volume 4  Chiba et al. 
challenged mice were significantly increased as compared 
with those of the control group (Fig. 2, Vehicle-Control vs 
Vehicle-Challenged groups; P<0.05). As previously reported 
[19, 20], most of the increased cells were eosinophils. The 
vehicle used had no effect on baseline lung histology and 
BAL cell counts and the airway inflammation induced by 
antigen exposure (data not shown). 
 
Fig. (2). Effects of intranasally administered sphingosine-1-
phosphate (S1P; 10
-5 M, 20 L) on cell number in bronchoalveolar 
lavage fluids (BALFs) obtained from control (Control) and 
repeatedly antigen-challenged (Challenged) mice. Each column 
represents the mean with SEM from 3 (Vehicle-Control) and 5 (the 
others) different animals. *P < 0.05 vs Vehicle-Control and ***P < 
0.001 vs S1P-Challenged by Bonferroni/Dunn’s test. The antigen-
induced increase in cell number was significantly augmented by the 
S1P treatment (Vehicle-Challenged vs S1P-Challenged, 
##P < 0.01 
by Bonferroni/Dunn’s test). 
  Recently, an involvement of sphingosine-1-phosphate 
(S1P) in the pathogenesis of allergic bronchial asthma has 
been suggested by the fact that S1P levels are elevated in the 
airways of asthmatics [7]. The current study revealed that, 
although the S1P administration alone had no effect on the 
lung histology (Fig. 1A, B ) and the BAL cell counts in 
control animals (Fig. 2, Vehicle-Control vs S1P-Control), 
administration of S1P prior to each antigen challenge 
aggravated the antigen-induced increase in BAL cell counts 
in mice (Fig. 2, Vehicle-Challenged vs S1P-Challenged 
groups; P<0.01). Different cell counts using Diff-Quik 
staining [19] revealed that the cell composition in BAL 
fluids of the S1P-Challenged group (macrophages: 
47.1±9.9%, eosinophils: 38.6±6.2%, lymphocytes: 
12.1±2.5%, and neutrophils: 2.2±1.1%) was similar to that of 
the Vehicle-Challenged one (48.9±10.1%, 37.8±5.6%, 
11.1±2.2% and 2.2±1.2%, respectively). An increase in the 
inflammation score was also observed in the lungs of the 
S1P-Challenged group (2.8±0.5), although the difference 
was not statistically significant when compared with that of 
the Vehicle-Challenged one (2.4±0.4, P>0.05). The results 
that S1P aggravated antigen-induced airway inflammation 
might be consistent with the previous report that 
pharmacological inhibition of sphingosine kinase (SphK) 
attenuated airway inflammation in mouse experimental 
asthma [9]. It is thus possible that endogenously released 
S1P is one of the mediators that play significant roles in the 
initiation and/or progression of allergic bronchial asthma. 
  Contrary to our results, Idzko and colleagues [14] 
reported that an intratracheal instillation of FTY720, an S1P 
receptor agonist, or S1P itself prior to each antigen 
inhalation abolished inflammatory cells infiltration into the 
airways in the BALB/c mice. Although the reason for the 
discrepancy is not known for certain, differences in the 
experimental conditions, such as difference in the protocols 
for antigen sensitization and inhalation, difference in the 
concentration and volume of S1P solution (20 L of 10
-5 M 
currently  vs 80 L of 10
-6 M in their study), and/or 
difference in the administration route of S1P (intranasally vs 
intratracheally, respectively), might be involved in it. While 
S1P and/or S1P receptor agonists, such as FTY720, have 
been suggested as a novel therapeutic strategy for airway 
inflammation [14, 21], further studies are required for 
making clear the exact role of S1P in the pathogenesis of 
allergic bronchial asthma. 
  In summary, the intranasal application of S1P caused an 
aggravation of airway inflammation induced by antigen 
exposure in a mouse model of allergic bronchial asthma. The 
results might raise a caution for clinical use of S1P receptor 
agonists, such as FTY720, in asthma treatment. 
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